GRAZ ,Austria, October 30 /PRNewswire/ -- ORIDIS Biomed, a biopharmaceutical company announced today that it has entered into a license agreement with the National Institutes of Health (NIH) for the worldwide commercial use of NIH’s proprietary Tissue Micro-Array (TMA) technology.
“We are pleased to have been granted by the NIH a license for this TMA technology”, said Georg Casari, PhD, Head of ORIDIS Biomed’s TISSOMICS(TM) business. “This license agreement further strengthens our TISSOMICS(TM) business for the life-science industry worldwide, where we offer our clients the ability to validate their research, such as biomarker and target verification programs.”
Tissue Micro-Arrays are a research tool, within ORIDIS Biomed’s TISSOMICS(TM) platform, that permits the rapid and simultaneous study of several hundred tissue samples, using standardized high-throughput analysis by in-house pathologists.
About NIH
Founded in 1887, the National Institutes of Health is one of the world’s foremost medical research centres, and the federal focal point for medical research funding in the United States. The NIH, comprising 27 separate Institutes and Centres, is one of eight health agencies of the Public Health Service which, in turn, is part of the U.S. Department of Health and Human Services.
About ORIDIS Biomed
ORIDIS Biomed commercializes its proprietary TISSOMICS(TM) platform in collaborations with industrial partners, as well as its own research and development programs.
ORIDIS Biomed is a biopharmaceutical company, developing therapeutics, diagnostics and biomarkers (targeted treatment solutions) for liver diseases. Therapeutic programs include primary liver cancer (hepatocellular carcinoma, HCC), and metabolic liver diseases, such as alcoholic steatohepatitis (ASH) and non-alcoholic steatohepatitis (NASH), where incidence rates are rapidly increasing due to modern life-styles, while treatment options are limited, expensive, and often ineffective.
ORIDIS Biomed is a privately held company, based in Graz, Austria.
About TISSOMICS(TM)
TISSOMICS(TM) is a proprietary disease-driven research platform enabling the medical validation of drug discovery approaches and biomarkers. The TISSOMICS(TM) research platform includes the use of optimized genomic and proteomic approaches, consistent quality assurance processes, and ORIDIS Biomed’s in-house pathology expertise for the interpretation of tissue analyses.
ORIDIS Biomed has a license from the Medical University of Graz, Austria for the commercial access to BioResource-Med biobank, one of the world’s largest collections of diseased human tissues and associated medical data.
TISSOMICS(TM) has been successfully applied in co-operations and partnerships with leading pharmaceutical and biotechnology companies to deliver medical validation to their drug discovery or biomarker programs.
For further information, please visit ORIDIS Biomed’s website at www.oridis-biomed.com
ORIDIS Biomed
CONTACT: Business Contact : Georg Casari, PhD, (Head of TISSOMICS(TM)),ORIDIS Biomed, Stiftingtalstrasse 3-5, A-8010 Graz, Austria,+43-316-3257760, info@oridis-biomed.com; Media Contact : FrankButschbacher, IR/Communications, +43-650-7844940, office@butschbacher.net
